CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,498 enrolled
Drug / intervention
tamoxifen +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00687102
NCT00687102Phase 3Completed
CompareCT.gov

Effects of Selective Estrogen Receptor Modulators on Cognitive Aging: Cognition in the Study of Tamoxifen and Raloxifene

Wake Forest University·interventional·Posted May 30, 2008·Updated Sep 12, 2018

In Brief

A Phase 3 clinical trial evaluating tamoxifen and raloxifene for Cognition and Aging. Completed, enrolled 1,498 participants across 134 sites in 2 countries.

Detailed Summary

The purpose of this study is to assess the effects of tamoxifen and raloxifene on cognitive aging in selected cognitively-healthy women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognition, Aging
CountriesCanada, United States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 30, 2008
Enrollment StartOct 1, 2001
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 18.1 years ago

Interventions

tamoxifendrug

oral tamoxifen plus placebo daily for 5 years

raloxifenedrug

oral raloxifene plus placebo daily for 5 years